UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes

Cell reports. Medicine, 2021-09, Vol.2 (9), p.100387-100387, Article 100387

2021

Volltextzugriff (PDF)

Body Composition Is the Main Determinant for the Difference in Type 2 Diabetes Pathophysiology Between Japanese and Caucasians

Diabetes care, 2014-03, Vol.37 (3), p.796-804

2014

Volltextzugriff (PDF)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.657-672

2016

Volltextzugriff (PDF)

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2238-2245

2018

Volltextzugriff (PDF)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population

Journal of diabetes investigation, 2022-04, Vol.13 (4), p.652-656

2022

Volltextzugriff (PDF)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.657-672

2016

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials

Clinical pharmacokinetics, 2021-10, Vol.60 (10), p.1335-1348

2021

Volltextzugriff (PDF)

Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development

CPT: pharmacometrics and systems pharmacology, 2015-10, Vol.4 (10), p.565-575

2015

Volltextzugriff (PDF)

Ethnic Differences in Insulin Sensitivity, β-Cell Function, and Hepatic Extraction Between Japanese and Caucasians: A Minimal Model Analysis

The journal of clinical endocrinology and metabolism, 2014-11, Vol.99 (11), p.4273-4280

2014

Volltextzugriff (PDF)

The Effects of a GLP‐1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model

CPT: pharmacometrics and systems pharmacology, 2015-01, Vol.4 (1), p.28-36

2015

Volltextzugriff (PDF)

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

CPT: pharmacometrics and systems pharmacology, 2016-07, Vol.5 (7), p.388-389

2016

Volltextzugriff (PDF)

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

CPT: pharmacometrics and systems pharmacology, 2013-10, Vol.2 (10), p.1-8

2013

Volltextzugriff (PDF)

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus

Clinical pharmacokinetics, 2016-11, Vol.55 (11), p.1457-1463

2016

Volltextzugriff (PDF)

Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea

Diabetes research and clinical practice, 2015-04, Vol.108 (1), p.113-119

2015

Volltextzugriff (PDF)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes

Diabetes therapy, 2019-04, Vol.10 (2), p.649-662

2019

Volltextzugriff (PDF)

Impact of demographics and disease progression on the relationship between glucose and HbA1c

European journal of pharmaceutical sciences, 2017-06, Vol.104, p.417-423

2017

Volltextzugriff (PDF)

Population Pharmacokinetics of Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice-Daily Exenatide

Journal of clinical pharmacology, 2010-08, Vol.50 (8), p.886-894

2010

Volltextzugriff (PDF)

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

CPT: pharmacometrics and systems pharmacology, 2014-07, Vol.3 (7), p.1-8

2014

Volltextzugriff (PDF)

Mathematical Modelling of Glucose‐Dependent Insulinotropic Polypeptide and Glucagon‐like Peptide‐1 following Ingestion of Glucose

Basic & clinical pharmacology & toxicology, 2017-10, Vol.121 (4), p.290-297

2017

Volltextzugriff (PDF)

Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

Journal of clinical pharmacology, 2012-12, Vol.52 (12), p.1815-1823

2012

Volltextzugriff (PDF)

Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart

Journal of clinical pharmacology, 2014-07, Vol.54 (7), p.809-817

2014

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin

Journal of pharmacokinetics and pharmacodynamics, 2003-06, Vol.30 (3), p.221-235

2003

Volltextzugriff (PDF)

Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study

Journal of neurology, neurosurgery and psychiatry, 1995-06, Vol.58 (6), p.681-687

1995

Volltextzugriff (PDF)

Safety and Pharmacokinetics of ReN1869: A First Human Dose Study in Healthy Subjects after Single-Dose Administration

Journal of clinical pharmacology, 2003-01, Vol.43 (1), p.66-73

2003

Volltextzugriff (PDF)

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test

Journal of pharmacokinetics and pharmacodynamics, 2011-12, Vol.38 (6), p.713-725

2011

Volltextzugriff (PDF)

1 – 25 von 165

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(145)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes

Body Composition Is the Main Determinant for the Difference in Type 2 Diabetes Pathophysiology Between Japanese and Caucasians

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials

Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development

Ethnic Differences in Insulin Sensitivity, β-Cell Function, and Hepatic Extraction Between Japanese and Caucasians: A Minimal Model Analysis

The Effects of a GLP‐1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus

Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes

Impact of demographics and disease progression on the relationship between glucose and HbA1c

Population Pharmacokinetics of Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice-Daily Exenatide

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

Mathematical Modelling of Glucose‐Dependent Insulinotropic Polypeptide and Glucagon‐like Peptide‐1 following Ingestion of Glucose

Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment

Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart

Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin

Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study

Safety and Pharmacokinetics of ReN1869: A First Human Dose Study in Healthy Subjects after Single-Dose Administration

Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test

Suchergebnisse filtern